Medite Cancer Company Insiders
| MDIT Stock | USD 0.0001 0.00 0.00% |
Medite Cancer employs about 69 people. The company is managed by 2 executives with a total tenure of roughly 8 years, averaging almost 4.0 years of service per executive, having 34.5 employees per reported executive. Breaking down Medite Cancer's management performance can provide insight into the firm performance.
| Jeffrey Rencher Insider Chief Officer |
| Susan Weisman Executive Consultant |
Medite |
Medite Cancer Management Team Effectiveness
The company has return on total asset (ROA) of (0.1368) % which means that it has lost $0.1368 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.737) %, meaning that it created substantial loss on money invested by shareholders. Medite Cancer's management efficiency ratios could be used to measure how well Medite Cancer manages its routine affairs as well as how well it operates its assets and liabilities.Medite Cancer Workforce Comparison
Medite Cancer Diagnostics is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 348. Medite Cancer retains roughly 69.0 in number of employees claiming about 20% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.65) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.49) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.49. Medite Cancer Diagnostics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Medite Cancer Diagnostics Price Series Summation is a cross summation of Medite Cancer price series and its benchmark/peer.
Medite Cancer Notable Stakeholders
A Medite Cancer stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Medite Cancer often face trade-offs trying to please all of them. Medite Cancer's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Medite Cancer's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jeffrey Rencher | Chief Officer | Profile | |
| Susan Weisman | Consultant | Profile |
About Medite Cancer Management Performance
The success or failure of an entity such as Medite Cancer Diagnostics often depends on how effective the management is. Medite Cancer management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Medite management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Medite management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Medite Cancer Diagnostics, Inc. operates as a medical technology company. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida. Medite Cancer operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 69 people.
Please note, the imprecision that can be found in Medite Cancer's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Medite Cancer Diagnostics. Check Medite Cancer's Beneish M Score to see the likelihood of Medite Cancer's management manipulating its earnings.
Medite Cancer Workforce Analysis
Traditionally, organizations such as Medite Cancer use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Medite Cancer within its industry.Medite Cancer Manpower Efficiency
Return on Medite Cancer Manpower
| Revenue Per Employee | 98.7K | |
| Revenue Per Executive | 3.4M | |
| Net Loss Per Employee | 98.7K | |
| Net Loss Per Executive | 3.4M |
Additional Tools for Medite Pink Sheet Analysis
When running Medite Cancer's price analysis, check to measure Medite Cancer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medite Cancer is operating at the current time. Most of Medite Cancer's value examination focuses on studying past and present price action to predict the probability of Medite Cancer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medite Cancer's price. Additionally, you may evaluate how the addition of Medite Cancer to your portfolios can decrease your overall portfolio volatility.